Profiling of modified citrus pectin oligosaccharide transport across Caco-2 cell monolayers

PharmaNutrition

Volumn 1, Issue 1, 2013, Pages 22-31

  Courts, Fraser L ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Caco 2; Galactooligosaccharides; Intestinal absorption; Modified citrus pectin; Oral bioavailability

Indexed keywords

ARABINOGALACTAN; FLUORESCEIN ISOTHIOCYANATE; GALACTAN; GALACTOSE OLIGOSACCHARIDE; GALACTURONIC ACID; LECTIN; MODIFIED CITRUS LECTIN; RHAMNOSE; UNCLASSIFIED DRUG;

ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; CARBOHYDRATE TRANSPORT; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE ABSORPTION; INTESTINE EPITHELIUM CELL; MASS SPECTROMETRY; MONOLAYER CULTURE; OLIGOMERIZATION; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN STRUCTURE; PROTEIN TRANSPORT; STRUCTURE ACTIVITY RELATION; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION;

EID: 84877965957     PISSN: 22134344     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phanu.2012.12.001     Document Type: Article

References (29)

1. Maxwell E.G., Belshaw N.J., Waldron K.W., Morris V.J. Pectin - an emerging new bioactive food polysaccharide. Trends in Food Science and Technology 2011, 24:64-73.
2. Sharma U.C., Pokharel S., van Brakel T.J., van Berlo J.H., Cleutjens J.P.M., Schroen B., et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004, 110:3121-3128.
3. Henderson N.C., Mackinnon A.C., Farnworth S.L., Poirier F., Russo F.P., Iredale J.P., et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:5060-5065.
4. Henderson N.C., Mackinnon A.C., Farnworth S.L., Kipari T., Haslett C., Iredale J.P., et al. Galectin-3 expression secretion links macrophages to the promotion of renal fibrosis. American Journal of Pathology 2008, 172:288-298.
5. Sharma U., Rhaleb N-E., Pokharel S., Harding P., Rasoul S., Peng H., et al. Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage. American Journal of Physiology. Heart and Circulatory Physiology 2008, 294:H1226-H1232.
6. Thandavarayan R.A., Watanabe K., Ma M., Veeraveedu P.T., Gurusamy N., Palaniyandi S.S., et al. 14-3-3 protein regulates Ask1 signaling and protects against diabetic cardiomyopathy. Biochemical Pharmacology 2008, 75:1797-1806.
7. Dumic J., Dabelic S., Flögel M. Galectin-3: an open-ended story. Biochimica et Biophysica Acta 2006, 1760:616-635.
8. Gunning A.P., Bongaerts R.J.M., Morris V.J. Recognition of galactan components of pectin by galectin-3. FASEB Journal 2009, 23:415-424.
9. DeBelder A.N., Granath K. Preparation and properties of fluorescein-labelled dextrans. Carbohydrate Research 1973, 30:375-378.
10. Hilgers A.R., Conradi R.A., Burton P.S. Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa. Pharmaceutical Research 1990, 7:902-910.
11. Maness N.O., Mort A.J. Separation and quantitation of galacturonic acid oligomers from 3 to over 25 residues in length by anion-exchange high-performance liquid chromatography. Analytical Biochemistry 1989, 178:248-254.
12. Blumenkrantz N., Asboe-Hansen G. New method for quantitative determination of uronic acids. Analytical Biochemistry 1973, 54:484-489.
13. Ma T.Y., Tran D., Hoa N., Nguyen D., Merryfield M., Tarnawski A. Mechanism of extracellular calcium regulation of intestinal epithelial tight junction permeability: role of cytoskeletal involvement. Microscopy Research and Technique 2000, 51:156-168.
14. Kaneo Y., Ueno T., Tanaka T., Iwase H., Yamaguchi Y., Uemura T. Pharmacokinetics and biodisposition of fluorescein-labeled arabinogalactan in rats. International Journal of Pharmaceutics 2000, 201:59-69.
15. Massarelli I., Murgia L., Bianucci A., Chiellini F., Chiellini E. Understanding the selectivity mechanism of the human asialoglycoprotein receptor (ASGP-R) toward Gal- and Man-type ligands for predicting interactions with exogenous sugars. International Journal of Molecular Sciences 2007, 8:13-28.
16. Robinson S., Bergström E., Seymour M., Thomas-Oates J. Screening of underivatized oligosaccharides extracted from the stems of Triticum aestivum using porous graphitized carbon liquid chromatography-mass spectrometry. Analytical Chemistry 2007, 79:2437-2445.
17. Ruhaak L., Deelder A., Wuhrer M. Oligosaccharide analysis by graphitized carbon liquid chromatography-mass spectrometry. Analytical and Bioanalytical Chemistry 2009, 394:163-174.
18. Domon B., Costello C.E. A systematic nomenclature for carbohydrate fragmentations in FAB-MS/MS spectra of glycoconjugates. Glycoconjugate Journal 1988, 5:397-409.
19. Artursson P., Ungell A-L., Löfroth J-E. Selective paracellular permeability in two models of intestinal absorption: cultured monolayers of human intestinal epithelial cells and rat intestinal segments. Pharmaceutical Research 1993, 10:1123-1129.
20. 2+ counterions. Macromolecular Chemistry and Physics 1980, 181:1059-1070.
21. Kolatsi-Joannou M., Price K.L., Winyard P.J., Long D.A. Modified citrus pectin reduces Galectin-3 expression and disease severity in experimental acute kidney injury. PLoS ONE 2011, 6:e18683.
22. Nangia-Makker P., Hogan V., Honjo Y., Baccarini S., Tait L., Bresalier R., et al. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. Journal of the National Cancer Institute 2002, 94:1854-1862.
23. Wang Y., Nangia-Makker P., Balan V., Hogan V., Raz A. Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment. Cell Death & Disease 2010, 1:e101.
24. Kolatkar A.R., Weis W.I. Structural basis of galactose recognition by C-type animal lectins. Journal of Biological Chemistry 1996, 271:6679-6685.
25. Burgess J.W., Stanley K.K. 17 alpha-ethinylestradiol increases transcytosis of asialoglycoproteins in rat liver. Journal of Biological Chemistry 1994, 269:3482-3488.
26. Mu J.Z., Fallon R.J., Swanson P.E., Carroll S.B., Danaher M., Alpers D.H. Expression of an endogenous asialoglycoprotein receptor in a human intestinal epithelial cell line, Caco-2. Biochimica et Biophysica Acta 1994, 1222:483-491.
27. Salama N.N., Eddington N.D., Fasano A. Tight junction modulation and its relationship to drug delivery. Advanced Drug Delivery Reviews 2006, 58:15-28.
28. Kamath A., Morrison R., Mathias N., Dando S., Marino A., Chong S. Modulation of tight junctions does not predict oral absorption of hydrophilic compounds: use of caco-2 and calu-3 cells. Archives of Pharmacal Research 2007, 30:1002-1007.
29. Kondoh M., Yagi K. Progress in absorption enhancers based on tight junction. Expert Opinion on Drug Delivery 2007, 4:275-286.